Abstract

In this perspective, the authors paint a vision for industrializing drug discovery with an "atoms and bits" approach. This approach leverages advancements in machine learning, automation, and biological tools to create a platform for drug discovery that de-specializes the output of insights and generates feedback loops to iterate on each success and failure. Recursion Pharmaceuticals, where the authors work, is provided as an example of how one company is attempting to achieve this vision.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call